peluntamig

Peluntamig (PT217) is a first-in-class, native IgG-like bispecific monoclonal antibody that targets both delta-like ligand 3 (DLL3) and CD47. It is being developed by Phanes Therapeutics for the treatment of small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and neuroendocrine prostate cancer (NEPC). The drug exerts its anti-tumor effects through multiple mechanisms, including inhibition of DLL3 protein and CD47 antigen, stimulation of macrophage activity, and induction of antibody-dependent cell cytotoxicity. Peluntamig has received orphan drug designations for SCLC and NEC as well as fast track designations from the FDA for extensive-stage SCLC with disease progression after platinum chemotherapy and metastatic or treatment-emergent NEPC. Clinical trials are ongoing in the US and China, with development currently in phase 1/2 for SCLC and NEC[1][2][3][4][5].

Brand names

peluntamig

Other names

Anti-DLL3/anti-CD47 bispecific antibody